StockNews.AI
ARTL
StockNews.AI
69 days

Artelo Biosciences Announces Reverse Stock Split

1. ARTL announces a 6-for-1 reverse stock split effective June 13, 2025. 2. The reverse split aims to meet Nasdaq's minimum price requirement of $1.00. 3. Shareholders' ownership percentage remains unchanged post-split. 4. Approximately 546,667 shares will be outstanding after the reverse split. 5. The split may influence investor perception and trading volume.

Stock Split
-1.6%Current Return
VS
+0.4%S&P 500
$1.206/11 09:38 PM EDTEvent Start
$1.180806/13 03:58 AM EDTLatest Updated
7m saved
Insight
Article

FAQ

Why Bullish?

The reverse split can attract institutional investors by raising share price, improving market perception. Historical trends show a positive correlation between reverse splits and investor interest, as seen with companies like Citron Research.

How important is it?

The article discusses a crucial corporate action that directly impacts share value and trading dynamics, making it very relevant for ARTL stakeholders.

Why Short Term?

The immediate effects on trading volumes and investor interest can be observed shortly after the split, but long-term impacts depend on operational success and product pipeline developments.

Related Companies

CANCACORCBAY
Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025 June 11, 2025 08:30 ET  | Source: Artelo Biosciences SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on May 20, 2025 Artelo’s Board of Directors approved a 6-for-1 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, June 13, 2025. The Board of Directors determined the 6-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to meet the continued listing requirement of the Nasdaq Stock Market (“Nasdaq”) of a minimum of $1.00 per share closing bid price. The new CUSIP number for the Common Stock following the Reverse Split will be 04301G607. As a result of the Reverse Split, each six shares of the Company’s issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the reverse split and no further action is required by shareholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the reverse split. Immediately after the reverse split becomes effective, there will be approximately 546,667 shares of Common Stock issued and outstanding. For further details, all shareholders are invited to review the 8-K regarding this reverse split which will be filed June 13, 2025. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio. Forward Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com

Related News